Orchestra BioMed (OBIO) Stock Price, News & Analysis

Company Overview

Orchestra BioMed, Inc. (NASDAQ: OBIO) is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies for inflammatory, fibrotic and oncologic diseases. The company’s research focuses on novel small-molecule programs designed to address high‐unmet-need conditions by leveraging proprietary prodrug and targeted inhibitor platforms. Orchestra BioMed’s pipeline includes lead candidates such as OBI-3424, a prodrug activated by AKR1C3 for the treatment of select solid tumors, and next-generation modulators aimed at suppressing pathological inflammation and fibrosis.

Orchestra BioMed conducts early‐ and mid-stage clinical studies in North America, working closely with key opinion leaders and academic centers to advance its programs. The company’s development strategy emphasizes streamlined trial design and biomarker-driven patient selection, with the goal of demonstrating safety and efficacy in well-defined patient populations. In parallel, Orchestra evaluates combination approaches and seeks strategic collaborations to broaden the therapeutic reach of its candidates across multiple disease indications.

Headquartered in the United States, Orchestra BioMed is led by a management team with extensive experience in drug discovery, clinical development and regulatory affairs. The company operates under a governance framework committed to scientific rigor and transparent communication with investors and collaborators. Orchestra BioMed continues to build its capabilities through targeted investments in research infrastructure and external partnerships, positioning itself to address significant challenges in fibrotic, inflammatory and oncologic disease management.

Key Stats

• Today's Range: $3.90 to $4.12
• 50-Day Range: $3.80 to $4.76
• 52-Week Range: $2.20 to $5.42
• Volume: 71,385 shs
• Average Volume: 202,672 shs
• Market Capitalization: $243.17 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $14.25
• Consensus Rating: Moderate Buy

Orchestra BioMed Stock Analysis - MarketRank™

Orchestra BioMed scored higher than 65% of companies evaluated by MarketBeat, and ranked 145th out of 860 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Orchestra BioMed has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 4 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Orchestra BioMed has a consensus price target of $14.25, representing about 250.9% upside from its current price of $4.06.

Amount of Analyst Coverage

Orchestra BioMed has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Orchestra BioMed are expected to grow in the coming year, from ($1.68) to ($1.48) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Orchestra BioMed is -3.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Orchestra BioMed is -3.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Orchestra BioMed has a P/B Ratio of 4.27. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.65% of the float of Orchestra BioMed has been sold short.

Short Interest Ratio / Days to Cover

Orchestra BioMed has a short interest ratio ("days to cover") of 7.54.

Change versus previous month

Short interest in Orchestra BioMed has recently decreased by 7.44%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Orchestra BioMed does not currently pay a dividend.

Dividend Growth

Orchestra BioMed does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 5 news articles for Orchestra BioMed this week, compared to 2 articles on an average week.

Search Interest

Only 1 people have searched for OBIO on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

MarketBeat Follows

1 people have added Orchestra BioMed to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 3.8 / 5
• Insider Trading: Acquiring Shares

Net Insider Buying

Over the last three months, insiders have purchased a net $42,900.00 in company stock, which represents 0.0176% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Orchestra BioMed insiders have bought more of their company's stock than they have sold. Specifically, they have bought $42,900.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

8.10% of the stock of Orchestra BioMed is held by insiders.

Percentage Held by Institutions

53.20% of the stock of Orchestra BioMed is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 3/12/2026
• Today: 5/08/2026
• Next Earnings (Estimated): 5/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:OBIO
• CIK: 1814114
• Web: orchestrabiomed.com
• Phone: 646-597-6980
• Fax: N/A
• Employees: 4
• Year Founded: 2018

Price Target and Rating

• Average Price Target for Orchestra BioMed: $14.25
• High Price Target: $20.00
• Low Price Target: $10.00
• Potential Upside/Downside: +250.9%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.13)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$52.70 million
• Net Margins: -157.40%
• Pretax Margin: -157.40%
• Return on Equity: -184.17%
• Return on Assets: -65.56%

Debt

• Debt-to-Equity Ratio: 0.27
• Current Ratio: 6.45
• Quick Ratio: 6.43

Sales & Book Value

• Annual Sales: $33.48 million
• Price / Sales: 7.26
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.95 per share
• Price / Book: 4.27

Miscellaneous

• Outstanding Shares: 59,880,000
• Free Float: 55,031,000
• Market Cap: $243.17 million
• Optionable: Not Optionable
• Beta: 0.52